Efficacy and Safety Results Following 12 Months of Maintenance Therapy with Lenalidomide or Daratumumab plus Lenalidomide

Conference Correspondent —December 16, 2020

The efficacy and safety of daratumumab (DARA), a human IgGκ monoclonal antibody targeting the CD38 antigen, was tested in transplant-eligible, newly diagnosed patients with multiple myeloma. The updated results of the phase 2 study are reported here.

In the primary analysis of the phase 2 GRIFFIN study (NCT02874742) in patients with transplant-eligible, newly diagnosed multiple myeloma, DARA plus lenalidomide, bortezomib, and dexamethasone (D-RVd) significantly improved rates of stringent complete response (sCR) by the end of post-transplant consolidation therapy versus RVd (Voorhees P, Blood. 2020). In this updated analysis, a total of 207 patients who were eligible for high-dose therapy (HDT) and autologous stem-cell transplant (ASCT) were randomized to RVd ± DARA in a 1:1 ratio. Patients were stratified by International Staging System (ISS) stage and creatinine clearance rate. The primary end point was rate of sCR at the end of post-ASCT consolidation per International Myeloma Working Group (IMWG) criteria. Key secondary end points included progression-free survival (PFS) and rate of minimal residual disease (MRD) negativity (10-5 threshold per IMWG criteria) assessed by next-generation sequencing.

Patients received 4 induction cycles, HDT, ASCT, 2 consolidation cycles, and maintenance with lenalidomide ± DARA for 24 months. During induction and consolidation, patients received lenalidomide 25 mg orally on days 1 to 14; bortezomib 1.3 mg/m2 subcutaneously on days 1, 4, 8, and 11; and dexamethasone 40 mg once weekly every 21 days. Intravenous DARA 16 mg/kg was given on days 1, 8, and 15 of cycles 1‐4 and day 1 of cycles 5‐6. During maintenance (cycles 7-32), patients received lenalidomide 10 mg (15 mg in cycles 10+ if tolerated) on days 1‐21 every 28 days ± intravenous DARA 16 mg/kg once every 8 weeks.

At the end of post-transplant consolidation, with a median follow-up of 13.5 months in the response-evaluable population, the sCR rate favored the D-RVd cohort versus RVd (42.4% [42/99] vs 32.0% [31/97]; 1-sided P = .0680). With additional D-R (lenalidomide) or lenalidomide maintenance therapy, responses continued to deepen and remained higher for the D-RVd group versus the RVd group. At the 12-months-of-maintenance therapy data cut (median follow-up, 26.7 months), the sCR rate still favored D-RVd versus RVd (63.6% [63/99] vs 47.4% [46/97]; 2-sided P = .0253). MRD-negativity (10-5) rates favored D-RVd treatment versus RVd (62.5% [65/104] vs 27.2% [28/103]; P <.0001), as well as among patients who achieved complete response (CR) or better at that time (76.5% [62/81]. Similarly, MRD-negativity (10-6) rates favored D-RVd versus RVd (26.9% [28/104] vs 12.6% [13/103]; P = .0140), as well as among patients who achieved CR or better at that time (34.6% [28/81] vs 18.6% [11/59]; P = .0555). Estimated 24-month PFS rates were 94.5% and 90.8% for the D-RVd and RVd groups, respectively. In total, 14 deaths occurred (n = 7 per group), and 9 were due to progressive disease (D-RVd, n = 5; RVd, n = 4). With the longer follow-up period, no new safety concerns were observed. A total of 84.8% (84/99) of patients in the D-RVd group and 79.4% (81/102) in the RVd group had grade 3/4 treatment-emergent adverse events (TEAEs). One grade 5 TEAE occurred in the RVd group, which was unrelated to study therapy. Infusion-related reactions occurred in 43.4% (43/99) of patients, with the majority being grade 1 or 2 and occurring in the first cycle.

After >2 years of median follow-up, the updated analysis demonstrated that the addition of DARA to RVd induction and consolidation, followed by D-R maintenance resulted in durable responses, including higher sCR and MRD-negativity rates, compared with lenalidomide alone. No new safety concerns were observed with the longer follow-up.


References

  1. Abstract 549. ASH 2020. December 7, 2020. Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of Griffin after 12 months of maintenance therapy.
  2. Voohees PM, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020 Aug 20;136(8):936-945.
Related Articles
Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
Conference Correspondent
The interim results from a phase 2 trial examining the response to ixazomib, lenalidomide, and dexamethasone induction in newly diagnosed, transplant-eligible patients showed an overall response rate of 93%.
Ciltacabtagene Autoleucel Is a BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy, in RRMM
Conference Correspondent
The preliminary results of the phase 1b/2 CARTITUDE-1 study revealed that early, deep, and durable responses were demonstrated and that a safety profile consistent with prior studies with a single low-dose infusion of ciltacabtagene autoleucel in heavily pretreated patients with RRMM was observed.
ANCHOR: Melflufen plus Dexamethasone and Daratumumab or Bortezomib in RRMM Refractory to an Immunomodulatory Drug and/or a Proteasome Inhibitor
Conference Correspondent
The updated efficacy and safety data from the ANCHOR study of melflufen plus dexamethasone and daratumumab or bortezomib in patients with RRMM demonstrated encouraging efficacy that was well-tolerated.
Last modified: December 16, 2020

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code